

Fast Solution-Phase and Liquid-Phase Peptide Syntheses (SolPPS and LPPS) Mediated by Biomimetic Cyclic Propylphosphonic Anhydride (T3P®)

Alexia Mattellone ¹, Dario Corbisiero ¹, Paolo Cantelmi ¹, Giulia Martelli ¹, Chiara Palladino ¹,
Alessandra Tolomelli ^{1,2,*}, Walter Cabri ^{1,2,*} and Lucia Ferrazzano ¹

¹ Tolomelli-Cabri/P4I Lab—Peptidomimetics and Peptides Targeting Protein-Protein Interaction, Department of Chemistry “Giacomo Ciamician”, Alma Mater Studiorum—University of Bologna, Via Gobetti 87, 40129 Bologna, Italy; alexia.mattellone2@unibo.it (A.M.); dario.corbisiero2@unibo.it (D.C.); pa.cantelmi@gmail.com (P.C.); giulia.martelli8@unibo.it (G.M.); chiara.palladino5@unibo.it (C.P.); lucia.ferrazzano4@unibo.it (L.F.)

² Consorzio C.I.N.M.P.I.S. (National Interuniversity Research Consortium in Innovative Synthesis Methodologies and Processes) c/o, Alma Mater Studiorum—University of Bologna, Via Gobetti 87, 40129 Bologna, Italy

* Correspondence: alessandra.tolomelli@unibo.it (A.T.); walter.cabri@unibo.it (W.C.); Tel.: +39-0512099575 (A.T.)

Table of Contents

1. HPLC Methods	S2
2. HPLC Chromatogram: Solvent suitability	S2
3. HPLC Chromatogram: Substrate scope	S10
4. Racemization evaluation	S16
5. HPLC chromatogram: SolPPS of Leu-Enkephalin precursor <i>via N</i> -Boc chemistry	S17
6. HPLC Chromatograms: Full LPPS of Leu-Enkephalin <i>via N</i> -Fmoc chemistry	S22
6.1 Epimers of Leu-Enkephalin synthesized by SPPS	S24
7. HPLC Chromatograms: Solvents and amino acids	S25
8. NMR spectra	S31

1. HPLC Methods


The gradient of analytical methods reported across the paper are defined as follow:

Method A		
Flow: 1 ml/min		
Time (min)	Mobile phase A (%)	Mobile phase B (%)
0	90	10
15	10	90
18	10	90
30	90	10

Method B		
Flow: 0.5 ml/min		
Time (min)	Mobile phase A (%)	Mobile phase B (%)
0	80	20
10	60	40
20	60	40
25	70	30
30	70	30

Method C		
Flow: 1 ml/min		
Time (min)	Mobile phase A (%)	Mobile phase B (%)
0	80	20
2	80	20
10	20	80
18	20	80
19	5	95
35	5	95
40	80	20
42	80	20

2. HPLC Chromatogram: Solvent suitability



Scheme S1. Model reaction for T3P[®] induced peptide synthesis.






Figure S1. Chromatogram of $\text{H}_2\text{N-Leu-OBn}$ at 220 nm (reference). The peak at 6.022 min is associated with *p*-Toluenesulphonic acid, as the counterion of the commercial leucine benzyl ester, and the peak at 9.434 min is related to $\text{H}_2\text{N-Leu-OBn}$.



Product	m/z observed	Rt (min)	Area (%)
<i>N</i> -Boc-Phe-Leu- OBn	469.0	16.755	96.8475
$\text{H}_2\text{N-Leu-OBn}$	222.1	12.460	3.1525

Figure S2. Chromatogram of *N*-Boc-Phe-Leu-OBn (**1a**) in DMF at 220 nm (entry 1, Table 1 in the article). The peaks around 3 min are associated with DMF (see chapter 7).



Product	m/z observed	Rt (min)
<i>N</i> -Fmoc-Phe-Leu-OBn	591.3	18.483

Figure S3. Chromatogram of *N*-Fmoc-Phe-Leu-OBn (**1b**) in DMF at 220 nm (entry 2, Table 1 in the article). The peaks around 3 min are associated with DMF (see chapter 7).




Figure S4. Chromatogram of *N*-Boc-Phe-Leu-OBn (**1a**) in DCM at 220 nm (entry 3, Table 1 in the article).




Figure S5. Chromatogram of *N*-Fmoc-Phe-Leu-OBn (**1b**) in DCM at 220 nm (entry 4, Table 1 in the article).




Figure S6. Chromatogram of *N*-Boc-Phe-Leu-OBn (**1a**) in Anisole at 220 nm (entry 5, Table 1 in the article). The peak at 13 min is associated with Anisole (see chapter 7).




Figure S7. Chromatogram of *N*-Fmoc-Phe-Leu-OBn (**1b**) in Anisole at 220 nm (entry 6, Table 1 in the article). The peak at 13 min is associated with Anisole (see chapter 7).




Figure S8. Chromatogram of *N*-Boc-Phe-Leu-OBn (**1a**) in CPME at 220 nm (entry 7, Table 1 in the article).




Figure S9. Chromatogram of *N*-Fmoc-Phe-Leu-OBn (**1b**) in CPME at 220 nm (entry 8, Table 1 in the article).




Figure S10. Chromatogram of *N*-Boc-Phe-Leu-OBn (**1a**) in EtOAc at 220 nm (entry 9, Table 1 in the article).




Figure S11. Chromatogram of *N*-Fmoc-Phe-Leu-OBn (**1b**) in EtOAc at 220 nm (entry 10, Table 1 in the article). The peak at 8 min is associated with EtOAc (see chapter 7).




Figure S12. Chromatogram of *N*-Boc-Phe-Leu-OBn (**1a**) in PrOAc at 220 nm (entry 11, Table 1 in the article).




Figure S13. Chromatogram of *N*-Fmoc-Phe-Leu-OBn (**1b**) in PrOAc at 220 nm (entry 12, Table 1 in the article). The peak at 11 min is associated with PrOAc (see chapter 7).




Figure S14. Chromatogram of *N*-Boc-Phe-Leu-OBn (**1a**) in tBuOAc at 220 nm (entry 13, Table 1 in the article). The peak at 12 min is associated with tBuOAc (see chapter 7).




Figure S15. Chromatogram of *N*-Fmoc-Phe-Leu-OBn (**1b**) in tBuOAc at 220 nm (entry 14, Table 1 in the article). The peak at 12 min is associated with tBuOAc (see chapter 7).




Figure S16. Chromatogram of *N*-Boc-Phe-Leu-OBn (**1a**) in DMC at 220 nm (entry 15, Table 1 in the article).




Figure S17. Chromatogram of *N*-Fmoc-Phe-Leu-OBn (**1b**) in DMC at 220 nm (entry 16, Table 1 in the article).




Figure S18. Chromatogram of *N*-Boc-Phe-Leu-OBn (**1a**) in THF at 220 nm (entry 17, Table 1 in the article).




Figure S19. Chromatogram of *N*-Fmoc-Phe-Leu-OBn (**1b**) in THF at 220 nm (entry 18, Table 1 in the article).




Figure S20. Chromatogram of *N*-Boc-Phe-Leu-OBn (**1a**) in ACN at 220 nm (entry 19, Table 1 in the article).




Figure S21. Chromatogram of *N*-Fmoc-Phe-Leu-OBn (**1b**) in ACN at 220 nm (entry 20, Table 1 in the article).




Figure S22. Chromatogram of *N*-Boc-Phe-Leu-OBn (**1a**) in NOP at 220 nm (entry 21, Table 1 in the article). The peak at 15 min is associated with NOP (see chapter 7).




Figure S23. Chromatogram of *N*-Fmoc-Phe-Leu-OBn (**1b**) in NOP at 220 nm (entry 22, Table 1 in the article). The peak at 15 min is associated with NOP (see chapter 7).

3. HPLC Chromatogram: Substrate scope

Chromatograms

The PG-amino acids were injected into the HPLC-MS with the same methods used for each reaction. In addition, for the reaction of 12, 13 and 14 entries (Table S2) samples were analyzed using a different method (Method C) due to elution difficulties.




Figure S24. Chromatogram of *N*-Boc-Leu-Leu-OMe in DCM at 220 nm (entry 1, Table 2 in the article).




Figure S25. Chromatogram of *N*-Boc-Phe-Leu-OMe in DCM at 220 nm (entry 2, Table 2 in the article).




Figure S26. Chromatogram of *N*-Boc-Arg(Pbf)-Leu-OMe in DCM at 220 nm (entry 3, Table 2 in the article).




Figure S27. Chromatogram of *N*-Boc-Asp(Bzl)-Leu-OMe in DCM at 220 nm (entry 4, Table 2 in the article).




Figure S28. Chromatogram of *N*-Boc-Ser-Leu-OMe in DCM at 220 nm (entry 5, Table 2 in the article).




Figure S29. Chromatogram of *N*-Boc-Thr-Leu-OMe in DCM at 220 nm (entry 6, Table 2 in the article).




Figure S30. Chromatogram of *N*-Boc-Trp-Leu-OMe in DCM at 220 nm (entry 7, Table 2 in the article).




Figure S31. Chromatogram of *N*-Boc-Aib-Leu-OMe in DCM at 220 nm (entry 8, Table 2 in the article).




Figure S32. Chromatogram of *N*-*N*-Fmoc-Leu-Leu-OBn in DCM at 220 nm (entry 9, Table 2 in the article).




Figure S33. Chromatogram of *N*-Fmoc-Trp-Leu-OBn in DCM at 220 nm (entry 10, Table 2 in the article).




Figure S34. Chromatogram of *N*-Fmoc-Arg(Pbf)-Leu-OBn in DCM at 220 nm (entry 11, Table 2 in the article).




Figure S35. Chromatogram of *N*-Fmoc-Asp(tBu)-Leu-OBn in DCM at 220 nm (entry 12, Table 2 in the article). The peak at 3 min is associated with *p*-Toluenesulfonic acid which is salified with H₂N-Leu-OBn.




Figure S36. Chromatogram of *N*-Fmoc-Ser(tBu)-Leu-OBn in DCM at 220 nm (entry 13, Table 2 in the article). The peak at 3 min is associated with p-Toluenesulfonic acid which is salified with H₂N-Leu-OBn.




Figure S37. Chromatogram of *N*-Fmoc-Thr(tBu)-Leu-OBn in DCM at 220 nm (entry 14, Table 2 in the article). The peak at 3 min is associated with p-Toluenesulfonic acid which is salified with H₂N-Leu-OBn.




Figure S38. Chromatogram of *N*-Fmoc-Arg-Leu-OBn in DCM at 220 nm (entry 15, Table 2 in the article).




Figure S39. Chromatogram of *N*-Fmoc-Aib-Leu-OBn in DCM at 220 nm (entry 16, Table 2 in the article).

4. Racemization evaluation

N-Boc-L/D-Phg-Leu-OMe was synthesized as described in the chapter “Materials and Methods” in the main paper. Each diastereomer and their mixture were injected into HPLC using chiral column working at 1 ml/min with Hexane and iPrOH (90:10).




Figure S40. Chromatogram of *N*-Boc-L-Phg-Leu-OMe in DCM at 220 nm.




Figure S41. Chromatogram of *N*-Boc-D-Phg-Leu-OMe in DCM at 220 nm.





Figure S42. Chromatogram of a mixture between *N*-Boc-L-Phg-Leu-OMe and *N*-Boc-D-Phg-Leu-OMe at 220 nm.

5. HPLC chromatogram: SolPPS of Leu-Enkephalin precursor *via N*-Boc chemistry

Intermediate isolation



Scheme S2. SolPPS of *N*-Boc-Leu-Enkephalin-OMe **7** (reported yields refer to crude reactions).




Figure S43. Chromatogram of intermediate *N*-Boc-Phe-Leu-OMe (**1c**) in the synthesis of Leu-Enkephalin precursor.




Figure S44. Chromatogram of intermediate TFA·H₂N-Phe-Leu-OMe (**2**) in the synthesis of Leu-Enkephalin precursor.




Figure S45. Chromatogram of intermediate *N*-Boc-Gly-Phe-Leu-OMe (**3**) in the synthesis of Leu-Enkephalin precursor.




Figure S46. Chromatogram of intermediate TFA·H₂N-Gly-Phe-Leu-OMe (4) in the synthesis of Leu-Enkephalin precursor.




Figure S47. Chromatogram of intermediate N-Boc-Gly-Gly-Phe-Leu-OMe (5) in the synthesis of Leu-Enkephalin precursor.




Figure S48. Chromatogram of intermediate TFA·H₂N-Gly-Gly-Phe-Leu-OMe (6) in the synthesis of Leu-Enkephalin precursor.




Figure S49. Chromatogram of Leu-Enkephalin precursor (**7**).

Continuous protocol




Figure S50. Chromatogram of intermediate *N*-Boc-Phe-Leu-OMe (**1c**) in the synthesis of Leu-Enkephalin precursor.




Figure S51. Chromatogram of intermediate H₂N-Phe-Leu-OMe (**2**) in the synthesis of Leu-Enkephalin precursor.




Figure S52. Chromatogram of intermediate *N*-Boc-Gly-Phe-Leu-OMe (**3**) in the synthesis of Leu-Enkephalin precursor.




Figure S53. Chromatogram of intermediate H₂N-Gly-Phe-Leu-OMe (**4**) in the synthesis of Leu-Enkephalin precursor.




Figure S54. Chromatogram of intermediate *N*-Boc-Gly-Gly-Phe-Leu-OMe (**5**) in the synthesis of Leu-Enkephalin precursor.




Figure S57. Chromatogram of Leu-Enkephalin in DCM precipitating after each step during the synthesis.




Figure S58. Chromatogram of Leu-Enkephalin in DCM precipitating after deprotection during the synthesis.




Figure S59. Chromatogram of Leu-Enkephalin in Anisole precipitating after each step during the synthesis.




Figure S60. Chromatogram of Leu-Enkephalin in Anisole precipitating after deprotection during the synthesis. The peak around 6 min is related to TFA added directly into the vial.

6.1 Epimers of Leu-Enkephalin synthesized by SPPS

To verify the stereochemical purity of the synthesized Leu-Enkephalin all the epimers as reference were synthesized through SPPS in DMF.

Manual syntheses of Leu-Enkephalin epimers were carried out at room temperature in glass syringes fitted with a polyethylene porous disc and connected to a vacuum source to remove excess reagents and solvents. The syntheses were carried out by using Wang-PS resin (200 mg, loading 1.2 mmol g⁻¹). After swelling of the resin in 2 mL of DMF, a solution of *N*-Fmoc-Leu-OH (or *N*-(D)-Fmoc-Leu-OH; 2.5 eq. respect to the loading of the resin), DIC (1.25 eq.) and DMAP (0.1 eq.) in DMF, preactivated for 5 min, was charged onto the resin and stirred for 1 h and the resin was washed with DMF (3x2 mL). The Fmoc protective group was removed by 20% piperidine in DMF (2 × 2 mL, 15 min each) and the resin was washed with DMF (3 × 2 mL). *N*-Fmoc-Phe-OH (or *N*-Fmoc-(D)-Phe-OH), *N*-Fmoc-Gly-OH and *N*-Fmoc-Tyr(tBu)-OH (or *N*-Fmoc-(D)-Tyr(tBu)-OH; 2 eq.) were diluted in DMF (2, 5 mL), pre-activated by DIC and OxymaPure® (3 eq.) for 3 min and coupled to the resin in 60 min. After each coupling step, the Fmoc protective group was removed by treating the peptide resin with a 20% piperidine solution in DMF (2 × 2 mL, 15 min each) and the resin was washed with DMF (3 × 2 mL). After the Fmoc-cleavage of the N-terminal alpha-amino group, the peptide resin was washed with DMF (3 × 2 mL) and DCM (3 × 2 mL). The dry peptide resin was suspended in 5 mL of the mixture TFA/TIS/H₂O (95/2.5/2.5 v/v/v) and stirred for 2 h. The resin was filtered off and diisopropylether (20 mL) cooled to 4 °C was added to the solution. The peptide was filtered and dried in vacuo to obtain crude epimers of Leu-Enkephalin. The relative chromatograms are reported in Fig. S61–S64.




Figure S61. Chromatogram of Leu-Enkephalin synthesized by SPPS.




Figure S62. Chromatogram of Leu-Enkephalin epimer with D-Leu synthesized by SPPS.




Figure S63. Chromatogram of Leu-Enkephalin epimer with D-Phe synthesized by SPPS.




Figure S64. Chromatogram of Leu-Enkephalin epimer with D-Tyr synthesized by SPPS.

7. HPLC Chromatograms: Solvents and amino acids

Solvents




Figure S65. Chromatogram of DMF.




Figure S66. Chromatogram of Anisole.




Figure S67. Chromatogram of PrOAc.




Figure S68. Chromatogram of tBuOAc.




Figure S69. Chromatogram of EtOAc.




Figure S70. Chromatogram of NOP.

Amino acids

Amino acids were injected into HPLC by analytical method A, described in Chapter 1 of this file. Only in the cases of *N*-Fmoc-Thr(*t*Bu)-OH, *N*-Fmoc-Ser(*t*Bu)-OH and *N*-Fmoc-Asp(*t*Bu)-OH, it was used method C because the respective dipeptides did not elute with the former method.




Figure S71. Chromatogram of *N*-Boc-Aib-OH.




Figure S72. Chromatogram of *N*-Boc-Arg(PBF)-OH.




Figure S73. Chromatogram of *N*-Boc-Asp(Bzl)-OH.




Figure S74. Chromatogram of *N*-Boc-Leu-OH.




Figure S75. Chromatogram of *N*-Boc-Phe-OH.




Figure S76. Chromatogram of *N*-Boc-Ser-OH.




Figure S77. Chromatogram of *N*-Boc-Trp-OH.




Figure S78. Chromatogram of *N*-Fmoc-Aib-OH.




Figure S79. Chromatogram of *N*-Fmoc-Arg(PBF)-OH.




Figure S80. Chromatogram of *N*-Fmoc-Arg(HCl)-OH.




Figure S81. Chromatogram of *N*-Fmoc-Asp(tBu)-OH.




Figure S82. Chromatogram of *N*-Fmoc-Leu-OH.




Figure S83. Chromatogram of *N*-Fmoc-Phe-OH.




Figure S84. Chromatogram of *N*-Fmoc-Ser(tBu)-OH.




Figure S85. Chromatogram of *N*-Fmoc-Thr(tBu)-OH.




Figure S86. Chromatogram of *N*-Fmoc-Trp-OH.

8. NMR spectra




Figure S87. ¹H-NMR (400 MHz, CDCl₃) spectra of 2,5-di(dococylloxy)benzaldehyde.




Figure S88. ¹³C-NMR (100 MHz, CDCl₃) spectra of 2,5-di(dococyloxy)benzaldehyde.




Figure S89. ¹H-NMR (400 MHz, CDCl₃) spectra of (2,5-bis(docosyloxy)phenyl)methanol.




Figure S90. ¹³C-NMR (100 MHz, CDCl₃) spectra of (2,5-bis(docosyloxy)phenyl)methanol.



Figure S91. ¹H-NMR (400 MHz, CDCl₃) spectra of N-Fmoc-Leu-Tag.




Figure S92. ^{13}C -NMR (100 MHz, CDCl_3) spectra of *N*-Fmoc-Leu-Tag.




Figure S93. ^1H -NMR (600 MHz, CDCl_3) spectra of H_2N -Leu-Tag.




Figure S94. ^{13}C -NMR (150 MHz, CDCl_3) spectra of $\text{H}_2\text{N-Leu-Tag}$.




Figure S95. ^1H -NMR (400 MHz, CDCl_3) spectra of $\text{N-Fmoc-Phe-Leu-Tag}$.




Figure S96. ^{13}C -NMR (100 MHz, CDCl_3) spectra of *N*-Fmoc-Phe-Leu-Tag.




Figure S97. ^1H -NMR (600 MHz, CDCl_3) spectra of H_2N -Phe-Leu-Tag.




Figure S98. ¹³C-NMR (150 MHz, CDCl₃) spectra of H₂N-Phe-Leu-Tag.




Figure S99. ¹H-NMR (600 MHz, CDCl₃) spectra of N-Fmoc-Gly-Gly-Phe-Leu-Tag.




Figure S100. ¹³C-NMR (150 MHz, CDCl₃) spectra of *N*-Fmoc-Gly-Gly-Phe-Leu-Tag.




Figure S101. ¹H-NMR (600 MHz, 20%MeOD in CDCl₃) spectra of *H*₂N-Gly-Gly-Phe-Leu-Tag.




Figure S102. ^{13}C -NMR (150 MHz, 20%MeOD in CDCl_3) spectra of $\text{H}_2\text{N-Gly-Gly-Phe-Leu-Tag}$.






Figure S103. ^1H -NMR (400 MHz, 20%MeOD in CDCl_3) spectra of $\text{N-Fmoc-Tyr(tBu)-Gly-Gly-Phe-Leu-Tag}$.






Figure S106. $^{13}\text{C-NMR}$ (150 MHz, CDCl_3) spectra of $\text{H}_2\text{N-Tyr(tBu)-Gly-Gly-Phe-Leu-Tag}$.